Before prescribing, please consult
the full package insert.
Copyright © 2013 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, U.S.A. All rights reserved.
INEGY S4 Each tablet contains 10 mg ezetimibe and 10, 20 or 40 mg simvastatin. Reg. No’s: 10/10 – A39/7.5/0031, 10/20 – A39/7.5/0032, 10/40 – A39/7.5/0033.
MSD (Pty) Ltd (Reg. No. 1996/003791/07), Private Bag 3, Halfway House 1685.
Tel: (011) 655-3000.
.
CARD-1098144-0000
46
%
51
%
55
%
10/10
10/20
10/40
…as demonstrated in a study conducted on
patients with hypercholesterolaemia
2
STUDY DESIGN: Goldberg et al:
A multicentre double-blind, placebo-controlled, factorial study enrolled 887 patients with hypercholesterolaemia (low-density lipoprotein cholesterol [LDL-C], 3.7 – 6.5 mmol/L (145 - 250 mg/dL): triglycerides,
<3.96 mmol/L (350 mg/dL)). Patients were randomised to 1 of 10 treatments – placebo, ezetimibe at 10 mg/d, simvastatin at 10, 20, 40, or 80 mg/d, or simvastatin at 10, 20, 40, or 80 mg/d plus ezetimibe at 10 mg/d for 12 weeks.The study
began March 13, 2001, and ended January 8, 2002.The primary efficacy end-point was the mean percent change in LDL-C levels from baseline to study end-point (last available past baseline LDL-C measurement) for the pooled ezetimibe/
simvastatin group vs the pooled simvastatin monotherapy group. Co-administration of ezetimibe/simvastatin was significantly (p<0.001) more effective than simvastatin alone in reducing LDL-C levels for the pooled ezetimibe/simvastatin
vs pooled simvastatin analysis and at each specific dose comparison.
REFERENCE:
1
. Shepherd J.The role of the exogenous pathway in hypercholesterolaemia. Eur Heart J Suppl. 2001;2(suppl E):E2–E5.
2
. Goldberg AC, Sapre A, Liu J, et al. for The Ezetimibe Study Group. Efficacy and Safety of Ezetimibe
Co-administered with Simvastatin in Patients With Primary Hypercholesterolaemia:A randomised, double-blind, Placebo-controlled trial. Mayo Clin Proc. 2004;79:620-629.
Powerful LDL-C reduction through
in a single tablet
1,2
For statin mono-therapy patients who are not at LDL-C Goal
